Skip to NavigationSkip to content

Analysts predict Pfizer to swallow GSK

Published on 21/05/15 at 02:25pm
Pfizer image

GlaxoSmithKline has been suggested as a potential M&A target for Pfizer, despite the US company backing out of a similar deal with UK firm AstraZeneca last year.

In a note to clients titled ‘Introducing PfizerKline’, analysts from Deutsche Bank have laid out the benefits that Pfizer could gain from purchasing the UK’s largest pharma company.

“Pfizer’s shareholder-friendly management team has previously stated that the company is open to acquisitions of various shapes and sizes. Regardless of whether Pfizer decides to split the company into pieces at some point, we believe that the company has a sense of urgency to create value by leveraging the power of its balance sheet to do needle-moving deals.

“As evidenced by Pfizer’s interest in AstraZeneca last year, one important goal for Pfizer has been to seek a deal that would maximize access to its balance sheet and improve its tax structure. Since media reports in the past have pointed to the potential for a Pfizer/GlaxoSmithKline combination, we are revisiting that theme and presenting a pro forma analysis of this potential combo.

“In short, this potential combination could be materially accretive to earnings per share and discounted cashflow, while allowing Pfizer to unlock access to its balance sheet and improve its tax situation over time.”

Lower UK tax rates were thought to be a key drive behind Pfizer’s attempted buyout of AstraZeneca, and the company lost interest shortly after the US introduced laws to curb the benefits of such overseas ‘tax inversion’ deals.

The acquisition would have created the world’s largest pharmaceutical company, but the proposal was met with much opposition from politicians, the British public, unions and scientists, and AstraZeneca rejected all of the US firm’s increasing offers.

It wasn’t long before Pfizer was back in the M&A arena though, as it went on to purchase Hospira for $17 billion this year in February.

However, analysts from Citigroup in London were quick to rebuff suggestions that Pfizer has its eye on GSK.

“We doubt that GSK is a viable acquisition target for Pfizer. While Pfizer could use its offshore cash to invert into GSK and lower its tax rate, we anticipate that government resistance to preserve GSK as an independent listed company is materially higher than it was with AstraZeneca, given the much larger UK infrastructure and GSK’s status as the largest UK pharmaceutical entity.”

George Underwood

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches